Mounjaro Beats Wegovy in Head-to-Head Weight-Loss Trial as Blockbuster Drug Reshapes Obesity in the US and UK
Eli Lilly's tirzepatide (Mounjaro/Zepbound) outperformed Novo Nordisk's Wegovy in a weight-loss trial, with users losing 20.2% body weight vs. 13.7%. Mounjaro became the world's top-selling drug, generating $8.7B in Q1 2026. U.S. obesity rates declined, and drug usage surged in the UK. Both drugs were initially developed for diabetes.
How this was made
The 30-second read
Why it matters
The core tradable takeaway is the quantified comparative efficacy advantage for tirzepatide, alongside ongoing blockbuster sales leadership, which can shift near-term expectations for obesity market share and formulary positioning.
Market read
Head-to-head efficacy results plus continued blockbuster momentum can drive relative valuation and positioning between the two obesity leaders.
What to watch
Insurance coverage, price changes, and long-term durability of weight loss and tolerability could matter as much as average weight-loss percentages.
Background
The article frames SURMOUNT-5 as the first head-to-head trial between tirzepatide (Lilly) and semaglutide (Novo Nordisk) for obesity without type 2 diabetes, and links it to broader US and UK adoption trends.
Ticker impact
The article reports SURMOUNT-5 head-to-head results showing tirzepatide (Mounjaro/Zepbound) lost 20.2% vs semaglutide 13.7% over 72 weeks.
Shares likely face upward pressure as markets price stronger competitive positioning and continued share gains in obesity.
The piece highlights a direct comparative efficacy advantage plus ongoing blockbuster sales momentum, which can support incremental demand expectations.
The article’s head-to-head SURMOUNT-5 comparison shows semaglutide (Wegovy) underperformed tirzepatide on average weight loss and responder rates.
Shares likely face downward pressure as investors reassess relative obesity franchise strength versus tirzepatide.
A non-blinded, but direct comparison with sizable efficacy differences can shift prescribing and insurance coverage decisions.
Market effects
Reinforces competitive dynamics in GLP-1 and dual-agonist obesity drugs, potentially affecting payer formulary decisions and channel demand.
Highlights US and UK uptake trends, supporting continued growth expectations for obesity therapeutics in both markets.
Comparative efficacy data can influence global prescribing norms and future trial designs across obesity pipelines.
Counterpoint
Because the trial was not blinded and used maximum tolerated doses, the efficacy gap may overstate real-world comparative outcomes and adherence effects.
Key entities
- companyEli Lilly
Developer of tirzepatide marketed as Mounjaro and Zepbound, reported to outperform semaglutide in SURMOUNT-5.
- companyNovo Nordisk
Developer of semaglutide marketed as Wegovy and Ozempic, reported to underperform tirzepatide in SURMOUNT-5.
- clinical_trialSURMOUNT-5 trial
Phase 3b head-to-head study comparing tirzepatide vs semaglutide in adults with obesity without type 2 diabetes.
